WE Med Tech secures tens of millions in Pre-C strategic funding to accelerate global expansion

Recently, WE Med Tech, the developer behind YOUMAGIC, completed a Pre-C round of financing. This round, amounting to tens of millions of RMB, was strategically invested by SBI, a globally renowned investment institution. The funds will be primarily utilized to deepen and upgrade the core technology research and development of YOUMAGIC, comprehensively construct clinical data systems and multi-center validation, establish Chinese and international registration and compliance capabilities, and build an internationalized team and organizational capacity.

This financing signifies strong international capital endorsement of YOUMAGIC's core technological strength, clinical value, and commercial potential, and also marks the official entry of YOUMAGIC's globalization strategy into a substantive implementation phase.

SBI is a leading comprehensive financial and investment group in Asia, with long-term and deep investments in sectors such as biomedicine, healthcare, and high-tech manufacturing. It possesses extensive industrial resources and a global capital network. Its investment logic consistently emphasizes long-term value, industrial synergy, and a global perspective. YOUMAGIC's technological moat, capacity for industrial upgrading, and internationalization potential formed the key foundation for this collaboration.

Examining global industry trends, the demand for anti-aging solutions is undergoing a profound transformation, evolving from mere "appearance improvement" towards deeper "tissue-level enhancement," significantly raising the industry's technological threshold. Only companies with core technological barriers and platform-based research and development capabilities can seize the initiative in this technological upgrade. YOUMAGIC possesses a clear technological roadmap and the capacity for sustained long-term research and development investment. It is not merely a single-product company but a platform-based enterprise capable of building an ecosystem, supporting product innovation and technological iteration across multiple categories and scenarios, thereby aligning with the core needs of the industry's advancing development.

WE Med Tech, the developer of YOUMAGIC, is centered on energy medicine. The company has established an integrated platform for energy medicine research and translation, encompassing research, development, production, and sales. Through systematic innovation, it has formed a difficult-to-replicate technological moat. Leveraging a series of innovative technologies—including 100ms flash pulse technology, a dynamic intelligent temperature control system, multi-level adjustable cooling technology, AI-based energy impedance matching, and visualized energy density—YOUMAGIC has achieved a breakthrough in high-energy monopolar radiofrequency technology. It has overcome the traditional limitation of "no pain, no gain" in radiofrequency anti-aging treatments, delivering a medical experience characterized by higher energy, greater comfort, and enhanced efficacy, establishing itself as a preferred anti-aging solution recognized by both physicians and consumers.

The potential for domestic substitution in China, robust potential in global competition, and the value of driving industrial upgrading are also key reasons behind YOUMAGIC's optimistic outlook. For a long time, the high-end medical device market in China has been dominated by overseas brands. Domestic Chinese brands now face a structural opportunity to break this monopoly. With its fully self-innovated core technologies across the entire chain, YOUMAGIC has taken the lead in disrupting the market monopoly, successfully seizing a critical development window.

On the global competition front, the safety and efficacy of YOUMAGIC products have been validated by both the China NMPA Class III medical device certification and the United States Food and Drug Administration clearance, demonstrating tangible strength for international competition. Clinical results show a 100% wrinkle improvement rate three months after YOUMAGIC treatment, with a 96.2% efficacy maintenance rate at six months, significantly outperforming comparable imported devices. At the industrial level, YOUMAGIC has deployed a dedicated production base in Wuxi, enabling the industrialization of its core technologies. This establishes a complete industrial cycle encompassing technology research and development, clinical validation, and industrial translation, providing solid foundational support and a practical model for the upgrading of the high-end medical device industry.

With the closing of the Pre-C round of financing, YOUMAGIC will gain strong financial backing, enabling systematic advancements in technological research and development, compliance positioning, organizational development, and international market expansion. It is also expected to leverage SBI's deep industrial resources and mature capital network within the global healthcare sector to accelerate its strategic moves in the international market, solidifying the foundation for its global expansion.

Technology and clinical evidence are the pivotal points of this strategic game. By harnessing the systematic synergy of resources and strategy, YOUMAGIC will increase research and development investment in high-energy monopolar radiofrequency and related energy medicine technologies, deepen scientific research collaborations with top-tier medical institutions and specialized physicians, continuously accumulate real-world clinical data, advance multi-center clinical validation, fortify its technological moat with robust evidence-based medicine, ensure technological innovation aligns closely with clinical needs, and iteratively upgrade its products.

The acceleration of international market positioning is also embedded within the details of compliance. Leveraging the foundation of its dual NMPA and Food and Drug Administration certifications, and supported by SBI's extensive international resources, YOUMAGIC will accelerate product registration and certification processes in markets across Europe, the Americas, South America, and the Middle East, paving standardized pathways for its products to reach the global stage.

At the globalization and ecosystem development level, YOUMAGIC will build a more experienced international team, formulate a clearer global development strategy, and enhance its global execution capabilities. It will also precisely connect with SBI's multidimensional resources—including research institutions, premium medical facilities, and professional channel partners worldwide—centered on technology collaboration and clinical co-development. This will promote deep integration of technological cooperation, academic exchange, and commercial implementation, thereby increasing international visibility and building global market channels and partnership ecosystems.

This strategic collaboration is not only a significant milestone in YOUMAGIC's development but also an important signal of Chinese high-end medical device enterprises going global. It fully demonstrates that the technological strength and commercial value of Chinese companies are internationally competitive, presenting new opportunities for industry revaluation.